Eradication of chronic hepatitis C virus infection improves the outcome of both liver and extrahepatic-related diseases and interferon-based regimens represented, for years, the standard of care to achieve this goal. Several baseline and on-treatment predictors of response, associated with a lower chance to achieve sustained virological response after interferon-based treatment, were developed. In the past few years, the advent of direct acting antivirals has dramatically modified the landscape of antiviral therapy, leading to an evolution from interferon-based to interferon-free therapies. This review will focus on the usefulness of futility stopping rules that allow the discontinuation of therapy in patients with a reduced chance to obtain sustained virological response if treated with interferon-containing regimens.
Boccaccio, V., Russo, M., Carbone, M., & Bruno, S. (2015). Treatment discontinuation with peg-interferon: What to consider. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 8(6), 761-768.
Citazione: | Boccaccio, V., Russo, M., Carbone, M., & Bruno, S. (2015). Treatment discontinuation with peg-interferon: What to consider. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 8(6), 761-768. |
Tipo: | Recensione in rivista |
Carattere della pubblicazione: | Scientifica |
Presenza di un coautore afferente ad Istituzioni straniere: | No |
Titolo: | Treatment discontinuation with peg-interferon: What to consider |
Autori: | Boccaccio, V; Russo, M; Carbone, M; Bruno, S |
Autori: | CARBONE, MARCO (Penultimo) |
Data di pubblicazione: | 2015 |
Lingua: | English |
Rivista: | EXPERT REVIEW OF CLINICAL PHARMACOLOGY |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1586/17512433.2015.1090872 |
Appare nelle tipologie: | 01 - Articolo su rivista |